Boston Scientific shares have fallen back to a price zone between $46.56 and $51.46 that has acted as support on six prior occasions, now trading around $49.01. The company has cut its full-year 2026 adjusted EPS guidance to a range of $3.28 to $3.32, citing a sharp slowdown in its U.S. WATCHMAN heart device market and unexpected competitive share losses in its Electrophysiology business. Management now expects limited adjusted EPS growth in 2027 and is guiding for global WATCHMAN revenue to decline mid- to high-single digits year-over-year in the second half of 2026. Excluding a multi-year advance that began in late 2023, prior defenses of this support level produced a median peak gain of 8.6% over holding periods of 11 to 47 days.
Abbott Laboratories
Becton Dickinson and Company
Johnson & JohnsonBoston Scientific CorpBoston Scientific cut 2026 EPS guidance due to slowdown in WATCHMAN market and competitive losses in Electrophysiology.
Stryker Corporation